Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) kicked off on Friday, down -3.58% from the previous trading day, before settling in for the closing price of $21.53. Over the past 52 weeks, ARWR has traded in a range of $17.05-$36.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -2.87% over the past five years. While this was happening, its average annual earnings per share was recorded 49.60%. With a float of $115.84 million, this company’s outstanding shares have now reached $124.38 million.
Let’s look at the performance matrix of the company that is accounted for 609 employees. In terms of profitability, gross margin is -282.15%, operating margin of -16927.06%, and the pretax margin is -17247.54%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc is 6.90%, while institutional ownership is 76.43%. The most recent insider transaction that took place on Jan 23 ’25, was worth 20,108. Before that another transaction happened on Jan 06 ’25, when Company’s Chief Discovery/Trans Medicine sold 32,729 for $19.82, making the entire transaction worth $648,824. This insider now owns 272,122 shares in total.
Arrowhead Pharmaceuticals Inc (ARWR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.60% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Take a look at Arrowhead Pharmaceuticals Inc’s (ARWR) current performance indicators. Last quarter, stock had a quick ratio of 6.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 727.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.00, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -3.41 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) saw its 5-day average volume 6.18 million, a positive change from its year-to-date volume of 3.13 million. As of the previous 9 days, the stock’s Stochastic %D was 78.91%. Additionally, its Average True Range was 1.16.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 36.05%, which indicates a significant decrease from 75.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.15% in the past 14 days, which was lower than the 66.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.76, while its 200-day Moving Average is $22.81. Nevertheless, the first resistance level for the watch stands at $21.54 in the near term. At $22.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.90. If the price goes on to break the first support level at $20.18, it is likely to go to the next support level at $19.59. Assuming the price breaks the second support level, the third support level stands at $18.82.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
The company with the Market Capitalisation of 2.58 billion has total of 124,434K Shares Outstanding. Its annual sales at the moment are 3,550 K in contrast with the sum of -599,490 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -170,540 K.
